Key Developments: Proteome Sciences PLC (PRM.L)

PRM.L on London Stock Exchange

27.75GBp
24 Dec 2014
Price Change (% chg)

1.12p (+4.19%)
Prev Close
26.88p
Open
28.00p
Day's High
28.00p
Day's Low
28.00p
Volume
32,303
Avg. Vol
201,998
52-wk High
43.00p
52-wk Low
21.00p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Proteome Sciences announces directorate change
Tuesday, 30 Sep 2014 02:03am EDT 

Proteome Sciences plc:Announces the appointment of Geoffrey Ellis as finance director with effect from Oct. 1.Says James Malthouse will remain as a director of the company until his retirement on Nov. 30.  Full Article

Proteome Sciences PLC gives FY 2015 revenue outlook
Tuesday, 30 Sep 2014 02:01am EDT 

Proteome Sciences PLC:Says strong growth in revenues is expected in FY 2015.FY 2015 revenue of 6.86 mln Pounds - Thomson Reuters I/B/E/S.  Full Article

Proteome Sciences plc signs $2 million contract with Genting TauRx Diagnostic Centre
Thursday, 25 Sep 2014 05:10am EDT 

Proteome Sciences plc:Signs $2 mln contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy London, Sept. 25, 2014.The project will involve PS analysing blood samples from patients enrolled in a phase 3 trial of the experimental Alzheimer's drug LMTX, targeting the tau pathway, and from age-matched controls.LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer's disease of mild to moderate severity.  Full Article

Proteome Sciences PLC announces holding interest of Helium Special Situations Fund
Friday, 28 Feb 2014 10:46am EST 

Proteome Sciences PLC:Says Helium Special Situations Fund holds 11,423,385 shares which represents 5.34 pct of direct voting rights of the company.  Full Article

Proteome Sciences PLC announces placing to raise five million Pounds
Monday, 24 Feb 2014 02:00am EST 

Proteome Sciences PLC:Has conditionally placed 17,857,143 new ordinary shares of one pence each to raise five million Pounds before expenses with new and existing investors at 28 pence per share to provide additional working capital for the company.Christopher Pearce, chief executive of the Proteome Sciences, has subscribed for 3,571,429 new ordinary shares in the placing at the placing price.Following this transaction christopher pearce will hold 35,109,504 ordinary shares in the company representing 16.4 pct of the company's enlarged share capital.The new ordinary shares will commence trading on or around Feb. 28.  Full Article

Proteome Sciences PLC Announces Discovery and Validation of Protein Biomarkers for Patient Stratification in Liver Cancer
Wednesday, 20 Nov 2013 02:00am EST 

Proteome Sciences PLC announced the discovery and validation of protein biomarkers for patient stratification in liver cancer using proteomics workflows. The study was performed in partnership with Professor Nigel Heaton and his team at Kings College Hospital NHS Foundation Trust and used PS Biomarker Services proteomic workflows. After completing the analysis of 2,864 proteins, a panel of differentially expressed biomarkers was identified and patents were filed prior to publication to cover these stratification markers.  Full Article

Proteome Sciences PLC Announces Share Subscription
Tuesday, 6 Aug 2013 08:10am EDT 

Proteome Sciences PLC announced that it received a direct approach from an institutional investor to subscribe for 3,750,000 new ordinary shares of GBP0.01 each at a price of GBP0.415 per share. The issue raised approximately GBP1.57 million which will be used as additional working capital to develop the business.  Full Article

Proteome Sciences PLC Comments On FY 2013 Revenue Guidance
Thursday, 30 May 2013 02:00am EDT 

Proteome Sciences PLC announced that for fiscal 2013, it expects a strong performance from licences, products and services that should result in a considerable uplift in fiscal 2013 revenue. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of GBP6.4 million for fiscal 2013.  Full Article

Proteome Sciences PLC Comments On FY 2013 Revenue Guidance
Tuesday, 22 Jan 2013 02:00am EST 

Proteome Sciences PLC announced that for fiscal 2013, it expects strong revenue growth across the Company's three main divisions. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of GBP6.5 million for fiscal 2013.  Full Article

Search Stocks